Inhibitors of histone deacetylase as antitumor agents: A critical review

Bioorganic Chemistry

Volumn 67, Issue , 2016, Pages 18-42

  Manal, Mohammed ^a   Chandrasekar, M J N ^a   Gomathi Priya, Jeyapal ^a   Nanjan, M J ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Anticancer activity; HDAC inhibitors; Histone deacetylase; Hydroxamic acids; Short chain fatty acids

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PANOBINOSTAT; ROMIDEPSIN; SHORT CHAIN FATTY ACID; VORINOSTAT; FATTY ACID; HISTONE DEACETYLASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY ACIDS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84970968588     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2016.05.005     Document Type: Review

References (203)

1. S. Khorasanizadeh The nucleosome from genomic organization to genomic regulation Cell 116 2004 259 272
2. S.K. Sharma, S. Hazeldine, M.L. Crowley, A. Hanson, R. Beattie, S. Varghese, T.M.D. Senanayake, A. Hirata, F. Hirata, Y. Huang, Y. Wu, N. Steingbergs, T. Murray-Stewart, I. Byetheway, R.A. Casero Jr., and P.M. Woster Polyamine-based small molecule epigenetic modulators Med. Chem. Commun. 3 2012 14 21
3. M.J. Pazin, and J.T. Kadonaga What's up and down with histone deacetylation and transcription? Cell 89 1997 325 328
4. R. Marmorstein, and S.Y. Roth Histone acetyltransferases: function, structure, and catalysis Curr. Opin. Genet. Dev. 11 2001 155 161
5. F.J. Dekker, and H.J. Haisma Histone acetyltransferases as emerging drug targets Drug Discov. Today 14 2009 942 948
6. H. Rajak, A. Singh, K. Raghuwanshi, R. Kumar, P.K. Dewangan, R. Veeraswamy, P.C. Sharma, A. Dixit, and P. Mishra A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity Curr. Med. Chem. 21 2014 2642 2664
7. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discov. 5 2006 769 784
8. I. Gregoretti, Y.-M. Lee, and H.V. Goodson Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J. Mol. Biol. 338 2004 17 31
9. M.C. Haigis, and L.P. Guarente Mammalian sirtuins emerging roles in physiology, aging and calorie restriction Genes Dev. 69 2006 1702 1705
10. T. Kozako, T. Suzuki, M. Yoshimitsu, N. Arima, S.I. Honda, and S. Soeda Anticancer agents targeted to sirtuins Molecules 19 2014 20295 20313
11. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, P.A. Marks, R. Breslow, and N.P. Pavletich Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188 193
12. D. Wang Computational studies on histone deacetylases and the design of selective histone deacetylase inhibitors Curr. Top. Med. Chem. 9 2009 241 256
13. S.D. Micco, M.G. Chini, S. Terracciano, I. Bruno, R. Riccio, and G. Bifulco Structural basis for the design and synthesis of selective HDAC inhibitors Bioorg. Med. Chem. 21 2013 3795 3807
14. J.R. Somoza, R.J. Skene, B.A. Katz, C. Mol, J.D. Ho, A.J. Jennings, C. Luong, A. Arvai, J.J. Buggy, E. Chi, J. Tang, B.C. Sang, E. Verner, R. Wynands, E.M. Leahy, D.R. Dougan, G. Snell, M. Navre, M.W. Knuth, R.V. Swanson, D.E. McRee, and L.W. Tari Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases Structure 12 2004 1325 1334
15. 2+-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. U.S.A. 101 2004 15064 15069
16. D.-F. Wang, P. Helquist, and O. Wiest Zinc binding in HDAC inhibitors: a DFT study J. Org. Chem. 72 2007 5446 5449
17. D.-F. Wang, O. Wiest, P. Helquist, H.Y. Lan-Hargest, and N.L. Wiech On the function of the 14 Å long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors J. Med. Chem. 47 2004 3409 3417
18. C.L. Hamblett, J.L. Methot, D.M. Mampreian, D.L. Sloman, M.G. Staton, A.M. Kral, J.C. Fleming, J.C. Cruz, M. Chenard, N. Ozerova, A.M. Hitz, H. Wang, S.V. Deshmukh, N. Nazef, A. Harsch, B. Hughes, W.K. Dahlberg, A.A. Szewczak, R.E. Middleton, R.T. Mosley, J.P. Secrist, and T.A. Miller The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 17 2007 5300 5309
19. A. Vannini, C. Volpari, P. Gallinari, P. Jones, M. Mattu, A. Carfi, R. De Francesco, C. Steinkuhler, and S. Di Marco Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 8 2007 879 884
20. E. Verdin, F. Dequiedt, and H.G. Kasler Class II histone deacetylases: versatile regulators Trends Genet. 19 2003 286 293
21. X.J. Yang, and S. Gregoire Class II histone deacetylases: from sequence to function, regulation, and clinical implication Mol. Cell. Biol. 25 2005 2873 2884
22. C. Hildmann, M. Ninkovic, R. Dietrich, D. Wegener, D. Riester, T. Zimmermann, O.M. Birch, C. Bernegger, P. Loidl, and A. Schwienhorst A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases J. Bacteriol. 8 2004 2328 2339
23. T.K. Nielsen, C. Hildmann, A. Dickmann, A. Schwienhorst, and R. Ficner Crystal structure of a bacterial class 2 histone deacetylase homologue J. Mol. Biol. 354 2005 107 120
24. D. Riester, D. Wegener, C. Hildmann, and A. Schwienhorst Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates Biochem. Biophys. Res. Commun. 324 2004 1116 1123
25. 2+ binding motif and cryptic deacetylase activity J. Biol. Chem. 283 2008 11355 11363
26. 2+ binding domain J. Biol. Chem. 283 2008 26694 26704
27. L. Guo, A. Han, D.L. Bates, J. Cao, and L. Chen Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains Proc. Natl. Acad. Sci. U.S.A. 104 2007 4297 4302
28. H.Y. Kao, C.H. Lee, A. Komarov, C.C. Han, and R.M. Evan Isolation and characterisation of mammalian HDAC 10, a novel histone deacetylase J. Biol. Chem. 277 2002 187 193
29. N.R. Bertos, B. Gilquin, M. Chan, T.J. Yen, S. Khochbin, and X.J. Yang A tetradecapeptide-repeat domain controls the leptomycin B-resistant cytoplasmic retention of human histone deacetylase 6 J. Biol. Chem. 279 2004 48246 48254
30. N.R. Bertos, A.H. Wang, and X.J. Yang Class II histone deacetylases: structure, function and regulation Biochem. Cell Biol. 79 2001 243 252
31. Y. Zhang, B. Gilquin, S. Khochbin, and P. Matthais Two catalytic domains are required for protein deacetylation J. Biol. Chem. 281 2006 2401 2404
32. L. Gao, M.A. Cueto, F. Asselberg, and P. Atadja Cloning and functional characterization of HDAC 11, a novel member of human deacetylase family J. Biol. Chem. 277 2002 25748 25755
33. R. Ficner Novel structural insights into class I and class II histone deacetylases Curr. Top. Med. Chem. 9 2009 235 240
34. C.A. Krusche, P. Wulfing, C. Kersting, A. Vloet, W. Bocker, L. Kiesel, H.M. Beier, and J. Alfer Histone deacetylase-1 and-3 protein expression in human breast cancer: a tissue microarray analysis Breast Cancer Res. Treat. 90 2005 15 23
35. Y. Minamiya, T. Ono, H. Saito, N. Takahashi, M. Ito, M. Mitsui, S. Motoyama, and J. Ogawa Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung Lung Cancer 74 2011 300 304
36. W. Weichert, A. Roske, V. Gekeler, T. Beckers, C. Stephan, K. Jung, F.R. Fritzsche, S. Neisporek, C. Denkert, M. Dietel, and G. Kristiansen Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy Br. J. Cancer 98 2008 604 610
37. W. Weichert, A. Roske, S. Neisporek, A. Noske, A.C. Buckendahl, M. Dietel, V. Gekeler, M. Boehm, T. Beckers, and C. Demkert Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo Clin. Cancer Res. 14 2008 1669 1677
38. T. Rikimaru, A. Taketomi, Y. Yamashita, K. Shirabe, T. Hamatsu, M. Shimada, and Y. Maehara Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma Oncology 72 2007 69 74
39. Y.W. Choi, S.M. Bae, Y.W. Kim, H.N. Lee, Y.W. Kim, T.C. Park, D.Y. Ro, J.C. Shin, S.J. Shin, J.S. Seo, and W.S. Ahn Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis Int. J. Gynecol. Cancer 17 2007 687 696
40. W. Weichert, A. Roske, V. Gekeler, T. Beckers, M.P. Ebert, M. Pross, M. Dietel, C. Denkert, and C. Rocken Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis Lancet Oncol. 9 2008 139 148
41. O. Witt, H.E. Deubzer, T. Milde, and I. Oehme HDAC family: what are the cancer relevant targets? Cancer Lett. 277 2009 8 21
42. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
43. D.S. Schrumps Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications Clin. Cancer Res. 15 2009 3947 3954
44. WAF1 expression and gene-associated histone acetylation Proc. Natl. Acad. Sci. U.S.A. 97 2000 10014 10019
45. CIP1/WAF1 Cancer Res. 63 2003 3637 3645
46. A. Vidal, and A. Koff Cell-cycle inhibitors: three families united by a common cause Gene 247 2000 1 15
47. T. Hitomi, Y. Matsuzaki, T. Yokota, Y. Takaoka, and T. Sakai P15 (INK4b) in HDAC-induced growth arrest FEBS Lett. 554 2003 347 350
48. A. Taddei, D. Roche, W.A. Bickmore, and G. Almouzni The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep. 6 2005 520 524
49. R. Venugopal, and T.R.J. Evans Developing histone deacetylase inhibitors as anti-cancer therapeutics Curr. Med. Chem. 18 2011 1658 1671
50. A.A. Ruefli, M.J. Ausserlechner, D. Bernhard, V.R. Sutton, K.M. Tainton, R. Kofler, M.J. Symth, and R.W. Johnstone The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species Proc. Natl. Acad. Sci. U.S.A. 98 2001 10833 10838
51. J.S. Ungerstedt, Y. Sowa, W.S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P.A. Marks Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc. Natl. Acad. Sci. U.S.A. 102 2005 673 678
52. L.M. Butler, X. Zhou, W.S. Xu, H.I. Scher, R.A. Rifkind, P.A. Marks, and V.M. Richon The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2 and downregulates thioredoxin Proc. Natl. Acad. Sci. U.S.A. 99 2002 11700 11705
53. J.H. Lee, M.L. Choy, L. Ngo, S.S. Foster, and P.A. Marks Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair Proc. Natl. Acad. Sci. U.S.A. 107 2010 14639 14644
54. S. Adimoolam, M. Sirisawad, J. Chen, P. Thiemann, J.M. Ford, and J.J. Buggy HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination Proc. Natl. Acad. Sci. U.S.A. 104 2007 19482 19487
55. H.Y. Cohen, S. Lavu, K.J. Bitterman, B. Hekking, T.A. Imahiyerobo, C. Miller, R. Frye, H. Ploegh, B.M. Kessler, and D.A. Sinclair Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis Mol. Cell 13 2004 627 638
56. A. Insinga, S. Monestiroli, S. Ronzoni, V. Gelmetti, F. Marchesi, A. Viale, L. Altucci, C. Nervi, S. Minucci, and P.G. Pelicci Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nat. Med. 11 2005 71 76
57. S. Minucci, and P.G. Pelicci Histone deacetylase Inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 6 2006 38 51
58. R.R. Rosato, S.C. Maggio, J.A. Almenara, S.G. Payne, P. Atadja, S. Spiegel, P. Dent, and S. Gant The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide Mol. Pharmacol. 69 2006 216 225
59. J.E. Bolden, W. Shi, K. Jankowski, C.Y. Kan, L. Cluse, B.P. Martin, K.L. MacKenzie, G.K. Smyth, and R.W. Johnstone HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses Cell Death Dis. 4 2013 e519 10.1038/cddis.2013.9
60. Y. Zhang, M. Adachi, R. Kawamura, and K. Imai Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis Cell Death Differ. 13 2006 129 140
61. Y. Shao, Z. Gao, P.A. Marks, and X. Jiang Apoptotic and autophagic cell death induced by histone deacetylase inhibitors Proc. Natl. Acad. Sci. U.S.A. 101 2004 18030 18035
62. D. Mahalingam, M. Mita, J. Sarantopoulos, L. Wood, R.K. Amaravadi, L.E. Davis, A.C. Mita, T.J. Curiel, C.M. Espitia, S.T. Nawrocki, F.J. Giles, and J.S. Carew Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors Autophagy 10 2014 1403 1414
63. W.S. Xu, G. Perez, L. Ngo, C.Y. Gui, and P.A. Marks Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects Cancer Res. 65 2005 7832 7839
64. C.F. Deroanne, K. Bonjean, S. Servotte, L. Devy, A. Colige, N. Clausse, N. Blacher, E. Verdin, J.-M. Foidart, B.V. Nusgens, and V. Castronovo Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signalling Oncogene 21 2002 427 436
65. D. Liang, X. Kong, and N. Sang Effects of histone deacetylase inhibitors on HIF-1 Cell Cycle 5 2006 2430 2435
66. R. Crazzolara, K. Johrer, R.W. Johnstone, R. Greil, R. Kofler, B. Meister, and D. Bernhard Histone deacetylases inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukemia Br. J. Haematol. 119 2002 965 969
67. M.S. Kim, H.J. Kwon, Y.M. Lee, J.H. Baek, J.E. Jang, S.W. Lee, E.J. Moon, H.S. Kim, S.K. Lee, H.Y. Chung, C.W. Kim, and K.-W. Kim Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nat. Med. 7 2001 437 443
68. T. Maeda, M. Towatari, H. Kosugi, and H. Saito Up-regulation of co-stimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells Blood 96 2000 3847 3856
69. W.J. Magner, A.L. Kazim, C. Stewart, M.A. Romano, G. Catalano, C. Grande, N. Keiser, F. Santaniello, and B.T. Tomasi Activation of MHC class I, II and CD40 gene expression by histone deacetylase inhibitors J. Immunol. 165 2000 7017 7024
70. S. Armeau, M. Bitzer, U.M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, A. Steinle, and H.R. Salih Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate Cancer Res. 65 2005 6321 6329
71. S. Skov, M.T. Pedersen, L. Andresen, P.T. Straten, A. Woetmann, and N. Odum Cancer cells become susceptible to natural cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class-I-related chain A and B Cancer Res. 65 2005 11136 11145
72. P. Reddy, Y. Maeda, K. Hotary, C. Liu, L.L. Reznikov, C.A. Dinarello, and J.L.M. Ferrara Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect Proc. Natl. Acad. Sci. U.S.A. 101 2004 3921 3926
73. K.M. Sakamoto, and G.I. Aldana-Masangkay The role of HDAC6 in cancer J. Biomed. Biotechnol. 2011 2011 1 10
74. A.D.-A. Tran, T.P. Marmo, A.A. Salam, S. Che, E. Finkelstein, R. Kabarriti, H.S. Xenias, R. Mazitschek, C. Hubbert, Y. Kawaguchi, M.P. Sheetz, T.-P. Yao, and J.C. Bulinski HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions J. Cell Sci. 120 2007 1469 1479
75. X. Zhang, Z. Yuan, Y. Zhang, S. Yong, A. Salas-Burgos, J. Koomen, N. Olashaw, J.T. Parsons, X.-J. Yang, S.R. Dent, T.-P. Yao, W.S. Lane, and E. Sato HDAC6 modulates cell motility by altering the acetylation level of cortactin Mol. Cell 27 2007 197 213
76. C. Estella, I. Herrer, S.P. Atkinson, A. Quiñonero, S. Martínez, A. Pellicer, and C. Simon Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion PLoS ONE 7 2012 e30508
77. M.Y. Ahn, D.O. Kang, Y.J. Na, S. Yoon, W.S. Choi, K.W. Kang, H.Y. Chung, J.H. Jung, D.S. Min, and H.S. Kim Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing Cancer Lett. 325 2012 189 199
78. U. De, S. Kundu, N. Patra, M.Y. Ahn, J.H. Ahn, J.Y. Son, J.H. Yoon, H.R. Moon, B.M. Lee, and H.S. Kim A new histone deacetylase inhibitor, MHY219, inhibits the migration of human prostate cancer cells via HDAC1 Biomol. Therapeut. 23 2015 434 441
79. Z.L. Yuan, Y.J. Guan, D. Chatterjee, and Y.E. Chin Stat3 dimerization regulated by reversible acetylation of a single lysine residue Science 307 2005 269 273
80. L. Chen, W. Fische, E. Verdin, and W.C. Greene Duration of nuclear NF-κB action regulated by reversible acetylation Science 293 2001 1653 1657
81. P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto, and K. Bhalla Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J. Biol. Chem. 280 2005 26729 26734
82. J.J. Kovacs, P.J. Murphy, S. Gaillard, X. Zhao, J.T. Wu, C.V. Nicchitta, M. Yoshida, D.O. Toft, W. Pratt, and T.P. Yao HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol. Cell 18 2005 601 607
83. M.H. Brush, A. Guardiola, J.H. Connor, T.P. Yao, and S. Shenolikar Deacetylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases J. Biol. Chem. 279 2004 7685 7691
84. C.S. Chen, S.C. Weng, P.H. Tseng, H.P. Lin, and C.S. Chen Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes J. Biol. Chem. 280 2005 38879 38887
85. Y. Kawaguchi, J.J. Kovacs, A. McLaurin, J.M. Vance, A. Ito, and T.P. Yao The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress Cell 115 2003 727 738
86. M. Mottamal, S. Zheng, T.L. Huang, and G. Wang Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents Molecules 20 2015 3898 3941
87. K.V. Balakin, Y.A. Ivanenkov, A.S. Kiselyov, and S.E. Tkachenko Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective Anti-Cancer Agents Med. Chem. 7 2007 576 592
88. O. Moradei, A. Vaisburg, and R.E. Martell Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents Curr. Top. Med. Chem. 8 2008 841 858
89. S.C. Mwakwari, V. Patil, W. Guerrant, and A.K. Oyelere Macrocyclic histone deacetylase inhibitors Curr. Top. Med. Chem. 10 2010 1423 1440
90. J. Li, G. Li, and W. Xu Histone deacetylase inhibitors: an attractive strategy for cancer therapy Curr. Med. Chem. 20 2013 1856 1886
91. H. Rajak, A. Singh, P.K. Dewangan, V. Patel, D.K. Jain, S.K. Tiwari, R. Veeraswamy, and P.C. Sharma Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity Curr. Med. Chem. 20 2013 1887 1903
92. V.G. Allfrey, R. Faulkner, and A.E. Mirsky Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proc. Natl. Acad. Sci. U.S.A. 51 1964 786 794
93. B.G. Pogo, V.G. Allfrey, and A.E. Mirsky RNA synthesis and histone acetylation during the course of gene activation in lymphocytes Proc. Natl. Acad. Sci. U.S.A. 55 1966 805 812
94. M.G. Riggs, R.G. Whittaker, J.R. Neumann, and V.M. Ingram N-butyrate causes histone modification in HeLa and Friend erythroleukaemia cells Nature 268 1977 462 464
95. G. Ginsburg, D. Salomon, T. Sreevalsan, and E. Freese Growth inhibition and morphological changes caused by lipophilic acids in mammalian cells Proc. Natl. Acad. Sci. U.S.A. 70 1973 2457 2461
96. A. Leder, and P. Leder Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells Cell 5 1975 319 322
97. Y. Furusawa, Y. Obata, S. Fukuda, T.A. Endo, G. Nakato, D. Takahashi, Y. Nakanishi, C. Uetake, K. Kato, T. Kato, M. Takahashi, N.N. Fukuda, S. Murakami, E. Miyauchi, S. Hino, K. Atarashi, S. Onawa, Y. Fujimura, T. Lockett, J.M. Clarke, D.L. Topping, M. Tomita, S. Hori, O. Ohara, T. Morita, H. Koseki, J. Kikuchi, K. Honda, K. Hase, and H. Ohno Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T Cells Nature 504 2013 446 450
98. K.N. Prasad, and K. Sinha Effect of sodium butyrate on mammalian cells in culture: a review Vitro 12 1976 125 132
99. C.B. Yoo, and P.A. Jones Epigenetic therapy of cancer: past, present and future Nat. Rev. Drug Discov. 5 2006 37 50
100. S.G. Sampathkumar, M.B. Jones, M.A. Meledeo, C.T. Campbell, S.S. Choi, K. Hida, P. Gomutputra, A. Sheh, T. Gilmartin, S.R. Head, and K.J. Yarema Targeting glycosylation pathways and the cell cycle: sugar dependent activity of butyrate-carbohydrate cancer prodrugs Chem. Biol. 13 2006 1265 1275
101. D. Riester, C. Hildmann, and A. Schwienhorst Histone deacetylase inhibitors - turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases Appl. Microbiol. Biotechnol. 75 2007 499 514
102. J. Kuroiwa-Trzmielina, A. De Conti, C. Scolastici, D. Pereira, M.A. Horst, E. Purgatto, T.P. Ong, and F.S. Moreno Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug Int. J. Cancer 124 2009 2520 2527
103. H.L. Newmark, J.R. Lupton, and C.W. Young Butyrate as a differentiating agent: pharmacokinetics, analogues and current status Cancer Lett. 78 1994 1 5
104. R.P. Warrell Jr., L.Z. He, V. Richon, E. Calleja, and P.P. Pandolfi Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J. Natl. Cancer Inst. 90 1998 1621 1625
105. S. Novich, L. Camacho, R. Gallagher, S. Chanel, R. Ho, T. Tolentino, V. Richon, P. Pandolfi, and R. Warrell Initial clinical evaluation of "transcription therapy" for cancer: all-trans retinoic acid plus phenyl butyrate Blood 94 1999 61a
106. K.M. Gilbert, A. De Loose, J.L. Valentine, and E.K. Fifer Structure-activity relationship between carboxylic acids and T cell cycle blockade Life Sci. 78 2006 2159 2165
107. A. Rephaeli, M. Entin-Meer, D. Angel, N. Tarasenko, T. Gruss-Fischer, I. Bruachman, D.R. Phillips, S.M. Cutts, D. Haas-Kogan, and A. Nudelman The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs Invest. New Drugs 24 2006 383 392
108. N. Tarasenko, A. Nudelman, I. Tarasenko, M. Entin-Meer, D. Hass-Kogan, A. Inbal, and A. Rephaeli Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex) Clin. Exp. Metastasis 25 2008 703 716
109. A. Rephaeli, R. Zhuk, and A. Nudelman Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications Drug Dev. Res. 50 2000 379 391
110. D. Blank-Porat, T. Gruss-Fischer, N. Tarasenko, Z. Malik, A. Nudelman, and A. Rephaeli The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties Cancer Lett. 256 2007 39 48
111. A. Mai, and L. Altucci Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead Int. J. Biochem. Cell Biol. 41 2009 199 213
112. N. Gupta, P.M. Martin, P.D. Prasad, and V. Ganapathy SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter Life Sci. 78 2006 2419 2425
113. V. Ganapathy, M. Thangaraju, and P.D. Prasad Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond Pharmacol. Therapeut. 121 2009 29 40
114. N. Elmouelhi, U. Aich, V.D.P. Paruchuri, M.A. Meledeo, C.T. Campbell, J.J. Wang, R. Srinivas, H.S. Khanna, and K.J. Yarema Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery J. Med. Chem. 52 2009 2515 2530
115. C.T. Campbell, U. Aich, C.A. Weier, J.J. Wang, S.S. Choi, M.M. Wen, K. Maisel, S.G. Sampathkumar, and M.J. Yarema Targeting proinvasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells J. Med. Chem. 51 2008 8135 8147
116. K. Steliou, M.S. Boosalis, S.P. Perrine, J. Sangerman, and D.V. Faller Butyrate histone deacetylase inhibitors Biores. Open Access 1 2012 192 198
117. S.R. Srinivas, P.D. Prasad, N.S. Umapathy, V. Ganapathy, and P.S. Shekhawat Transport of butyryl-l-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+) Am. J. Physiol. Gastrointest. Liver Physiol. 293 2007 G1046 G1053
118. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252
119. FDA Approves Beleodaq to Treat Rare, Aggressive Form of Non-Hodgkin Lymphoma. < http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.html > (accessed 12.10.15).
120. H. Bailey, D.D. Stenehjem, and S. Sharma Panobinostat or the treatment of multiple myeloma: the evidence to date J. Blood Med. 6 2015 269 276
121. H. Wang, and B.W. Dymock New patented histone deacetylase inhibitors Expert Opin. Ther. Patents 19 2009 1727 1757
122. L. Zhang, H. Fang, and W. Xu Strategies in developing promising histone deacetylase inhibitors Med. Res. Rev. 30 2010 585 602
123. S.S. Ramalingam, C.P. Belani, C. Ruel, P. Frankel, B. Gitlitz, M. Kcozywas, I. Espinoza-Delgado, and D. Gandara Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma J. Thorac. Oncol. 4 2009 97 101
124. J. Golay, L. Cuppinni, F. Leoni, C. Mico, V. Barbui, M. Domenghini, L. Lombardi, A. Neri, A.M. Barbui, A. Salvi, P. Pozzi, G. Porro, P. Pagani, G. Fossali, P. Mascagni, M. Introna, and A. Rambaldi The histone deacetylase inhibitor ITF2357 has antileukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells Leukemia 21 2007 1892 1900
125. O.H. Kramer, M. Gottlicher, and T. Heinzel Histone deacetylase as a therapeutic target Expert Opin. Investig. Drugs 19 2010 1049 1066
126. S.J. Haggarty, K.M. Koeller, J.C. Wong, C.M. Grozinger, and S.L. Schreiber Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc. Natl. Acad. Sci. U.S.A. 100 2003 4389 4394
127. K.V. Butler, J. Kalin, C. Brochier, G. Vistoli, B. Langley, and A.P. Kozikowski Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 132 2010 10842 10846
128. R. Lavoie, G. Bouchain, S. Frechette, S.H. Woo, E.A. Khalil, S. Leit, M. Fournel, P.T. Yan, M.-C. Tracy-Bourget, C. Beaulieu, Z. Li, J. Besterman, and D. Delorme Design and synthesis of a novel class of histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 11 2001 2847 2850
129. D. Delorme, R. Ruel, R. Lavoie, C. Thibault, E. Abou-Khalil, W.O. Patent 01/38322 A1, 2001. Inhibitors of histone deacetylase, Chem. Abstr. 135 (2001) 5455.
130. C.M. Marson, N. Serradji, A.S. Rioja, S.P. Gaustaud, J.P. Alao, R.C. Coombes, and D.M. Vigushin Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2.; 4-dienoic acid hydroxyamides Bioorg. Med. Chem. Lett. 14 2004 2477 2481
131. M.L. Curtin, R.B. Garland, H.R. Heyman, R.R. Frey, M.R. Michaelides, J. Li, L.J. Pease, K.B. Glaser, P.A. Marcotte, and S.K. Davidsen Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC) Bioorg. Med. Chem. Lett. 12 2002 2919 2923
132. S. Uesato, M. Kitagawa, Y. Nagaoka, T. Maeda, H. Kuwajima, and T. Yamori Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group Bioorg. Med. Chem. Lett. 12 2002 1347 1349
133. T. Yamori, A. Matsunaga, S. Sato, K. Yamazaki, A. Komi, K. Ishizu, I. Mita, H. Edatsugi, Y. Matsuba, K. Takezawa, O. Nakanishi, H. Kohno, Y. Nakajima, H. Komatsu, T. Andoh, and T. Tsuruo Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel Cancer Res. 59 1999 4042 4049
134. Y. Dai, Y. Guo, J. Guo, L.J. Pease, J. Li, P.A. Marcotte, K.B. Glaser, P. Tapang, D.H. Albert, P.L. Richardson, S.K. Davidsen, and M.R. Michaelides Indole amide hydroxamic acids as potent inhibitors of histone deacetylases Bioorg. Med. Chem. Lett. 13 2003 1897 1901
135. Y. Dai, Y. Guo, M.L. Curtin, J. Li, L.J. Pease, J. Guo, P.A. Marcotte, K.B. Glaser, S.K. Davidsen, and M.R. Michaelides A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units Bioorg. Med. Chem. Lett. 13 2003 3817 3820
136. T. Suzuki, Y. Nagano, A. Matsuura, A. Kohara, S. Ninomiya, K. Kohda, and N. Miyata Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates Bioorg. Med. Chem. Lett. 13 2003 4321 4326
137. T. Suzuki, A. Matsuura, A. Kouketsu, S. Hisakawa, H. Nakagawa, and N. Miyata Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent Bioorg. Med. Chem. Lett. 13 2005 4332 4342
138. C. Shinji, T. Nakamura, S. Maeda, M. Yoshida, Y. Hashimoto, and H. Miyachi Design and synthesis of phthalimide-type histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 15 2005 4427 4431
139. C. Shinji, S. Maeda, K. Imai, M. Yoshida, Y. Hashimoto, and H. Miyachi Design, synthesis and evaluation of -cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 14 2006 7625 7651
140. S. Lee, C. Shinji, K. Ogura, M. Shimizu, S. Maeda, M. Sato, M. Yoshida, Y. Hashimotoa, and H. Miyachia Design, synthesis and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 17 2007 4895 4900
141. A. Mai, S. Massa, D. Rotili, R. Pezzi, P. Bottoni, R. Scatena, J. Meraner, and G. Brosch Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-HDAC inhibitors based hydroxamates Bioorg. Med. Chem. Lett. 15 2005 4656 4661
142. K. Krennhrubec, B.L. Marshall, M. Hedglin, E. Verdin, and S.M. Ulrich Design and evaluation of linkerless hydroxamic acids as selective HDAC8 inhibitors Bioorg. Med. Chem. Lett. 17 2007 2874 2878
143. P. Tessier, D.V. Smil, A. Wahhab, S. Leit, J. Rahil, Z. Li, R. Deziel, and J.M. Besterman Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 19 2009 5684 5688
144. D.J. Witter, S. Belvedere, L. Chen, P. Secrist, R.T. Mosley, and T.A. Miller Benzo[b]thiophene-based histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 17 2007 4562 4567
145. S. Price, W. Bordogna, R.J. Bull, D.E. Clark, P.H. Crackett, H.J. Dyke, M. Gill, N.V. Harris, J. Gorski, J. Lloyd, P.M. Lockey, J. Mullett, A.G. Roach, F. Roussel, and A.B. White Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 17 2007 370 375
146. S. Price, W. Bordogna, R. Braganza, R.J. Bull, H.J. Dyke, S. Gardan, M. Gill, N.V. Harris, R.A. Heald, M.v.D. Heuvel, P.M. Lockey, J. Lloyd, A.G. Molina, A.G. Roach, F. Roussel, J.M. Sutton, and A.B. White Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 17 2007 363 369
147. C. Charrier, J. Roche, J.-P. Gesson, and P. Bertrand Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues Bioorg. Med. Chem. Lett. 17 2007 6142 6146
148. C. Charrier, J. Clarhaut, J.-P. Gesson, G. Estiu, O. Wiest, J. Roche, and P. Bertrand Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression J. Med. Chem. 52 2009 3112 3115
149. P.C. Chen, V. Patil, W. Guerrant, P. Green, and A.K. Oyelere Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap Bioorg. Med. Chem. Lett. 16 2008 4839 4853
150. R. He, Y. Chen, Y. Chen, A.V. Ougolkov, J.S. Zhang, D.N. Savoy, D.D. Billadeau, and A.P. Kozikowski Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents J. Med. Chem. 53 2010 1347 1356
151. T. Suzuki, Y. Ota, M. Ri, M. Bando, A. Gotoh, Y. Itoh, H. Tsumoto, P.R. Tatum, T. Mizukami, H. Nakagawa, S. Iida, R. Ueda, K. Shirahige, and N. Miyata Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries J. Med. Chem. 55 2012 9562 9575
152. T. Suzuki, N. Muto, M. Bando, Y. Itoh, A. Masaki, M. Ri, Y. Ota, H. Nakagawa, S. Iida, K. Shirahige, and N. Miyata Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors Chem. Med. Chem. 9 2014 657 664
153. H. Wang, N. Yu, H. Song, D. Chen, Y. Zou, W. Deng, P.L. Lye, J. Chang, M. Ng, S. Blanchard, E.T. Sun, K. Sangthongpitag, X. Wang, K.C. Goh, X. Wu, H.H. Khng, L. Fang, S.K. Goh, W.C. Ong, Z. Bonday, W. Stünkel, A. Poulsen, and M. Entzeroth N-hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors. Design, synthesis, SAR studies, and in vivo antitumor activity Bioorg. Med. Chem. Lett. 19 2009 1403 1408
154. J.C. Bressi, R.D. Jong, Y. Wu, A.J. Jennings, J.W. Brown, S. O'Connell, L.W. Tari, R.J. Skene, P. Vu, M. Navre, X. Cao, and A.R. Gangloff Benzimidazole and imidazole inhibitors of histone deacetylases: synthesis and biological activity Bioorg. Med. Chem. Lett. 20 2010 3138 3141
155. S. Tapadar, R. He, D.N. Luchini, D.D. Billadeau, and A.P. Kozikowski Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity Bioorg. Med. Chem. Lett. 19 2009 3023 3026
156. P. Conti, L. Tamborini, A. Pinto, L. Sola, R. Ettari, C. Mercurio, and C.D. Micheli Design and synthesis of novel isoxazole-based HDAC inhibitors Eur. J. Med. Chem. 45 2010 4331 4338
157. J. Jiao, H. Fang, X. Wang, P. Guan, Y. Yuan, and W. Xu Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors Eur. J. Med. Chem. 44 2009 4470 4476
158. S. Dallavalle, R. Cincinelli, R. Nannei, L. Merlini, G. Morini, S. Penco, C. Pisano, L. Vesci, M. Barbarino, V. Zuco, M.D. Cesare, and F. Zunino Design, synthesis and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors Eur. J. Med. Chem. 44 2009 1900 1912
159. H. Wang, Z.Y. Lim, Y. Zhou, M. Ng, T. Lu, K. Lee, K. Sangthongpitag, K.C. Goh, X. Wang, X. Wub, H.H. Khng, S.K. Goh, W.C. Ong, Z. Bonday, and E.T. Sun Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors, synthesis, SAR, and in vivo antitumor activity Bioorg. Med. Chem. Lett. 20 2010 3314 3321
160. V. Tazzari, G. Cappalletti, M. Casagrande, E. Perrino, L. Renzi, P.D. Saldato, and A. Sparatore New aryldithiolethione derivatives as potent histone deacetylase inhibitors Bioorg. Med. Chem. 18 2010 4187 4194
161. H.C. Yoon, E. Choi, J.E. Park, M. Cho, J.J. Seo, S.J. Oh, S.J. Kang, H.M. Kim, S.K. Park, K. Lee, and G. Han Property based optimization of δ-lactam HDAC inhibitors for metabolic Bioorg. Med. Chem. Lett. 20 2010 6808 6811
162. H.M. Kim, D.K. Ryu, Y. Choi, B.W. Park, K. Lee, S.B. Han, C.W. Lee, M.R. Kang, J.S. Kang, S.K. Boovanahalli, S.K. Park, J.W. Han, T.G. Chun, H.Y. Lee, K.Y. Nam, E.H. Choi, and G. Han Structure-activity relationship studies of a series of novel δ-lactam based histone deacetylase inhibitors J. Med. Chem. 50 2007 2737 2741
163. H.M. Kim, S.H. Hong, M.S. Kim, C.W. Lee, J.S. Kang, K. Lee, S.K. Park, J.W. Han, H.Y. Lee, Y. Choi, H.J. Kwon, and G. Han Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 17 2007 6234 6238
164. E. Choi, C. Lee, J.E. Park, J.J. Seo, M. Cho, J.S. Kang, H.M. Kim, S.K. Park, K. Lee, and G. Han Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors Bioorg. Med. Chem. Lett. 21 2011 1218 1221
165. C. Lee, E. Choi, M. Cho, B. Lee, J.S. Oh, J.S. Kang, S.K. Park, K. Lee, H.M. Kim, and G. Han Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II Bioorg. Med. Chem. Lett. 22 2012 4189 4192
166. S. Belvedere, D.J. Witter, J. Yan, J.P. Secrist, V. Richona, and T.A. Millera Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors Bioorg. Med. Chem. Lett. 17 2007 3969 3971
167. M. Taddei, E. Cini, L. Giannotti, G. Giannini, G. Battistuzzi, D. Vignola, L. Vesci, and W. Cabri Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors Bioorg. Med. Chem. Lett. 24 2014 61 64
168. H. Rajak, A. Agarawal, P. Parmar, B.S. Thakur, R. Veerasamy, P.C. Sharma, and M.D. Kharya 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 21 2011 5735 5738
169. P. Guan, L. Wang, X. Hou, Y. Wan, W. Xu, W. Tang, and H. Fang Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif Bioorg. Med. Chem. 22 2014 5766 5775
170. J. Cai, H. Wei, K.H. Hong, X. Wu, X. Zong, M. Cao, P. Wang, L. Li, C. Sun, B. Chen, G. Zhou, J. Chen, and M. Ji Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents Bioorg. Med. Chem. 23 2015 3457 3471
171. Y. Yao, C. Liao, Z. Li, Z. Wang, Q. Sun, C. Liu, Y. Yang, Z. Tu, and S. Jiang Design, synthesis and biological evaluation of 1,3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors Eur. J. Med. Chem. 86 2014 639 652
172. M. Binaschi, A. Boldetti, M. Gianni, C.A. Maggi, M. Gensini, M. Bigioni, M. Parlani, A. Giolitti, M. Fratelli, C. Valli, M. Terao, and E. Garattini Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors ACS Med. Chem. Lett. 1 2010 411 415
173. M. Bigioni, A. Ettorre, P. Felicetti, S. Mauro, C. Rossi, C.A. Maggi, E. Marastoni, M. Binaschi, M. Parlani, and D. Fattori Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures Bioorg. Med. Chem. Lett. 22 2012 5360 5362
174. M. Varasi, F. Thaler, A. Abate, C. Bigogno, R. Boggio, G. Carenzi, T. Cataudella, R.D. Zuffo, M.C. Fulco, M.G. Rozio, A. Mai, G. Dondio, S. Minucci, and C. Mercurio Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors J. Med. Chem. 54 2011 3051 3064
175. C. Pabba, B.T. Gregg, D.B. Kitchen, Z.J. Chen, and A. Judkins Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 21 2011 324 328
176. Y. Zhu, X. Chen, Z. Wu, Y. Zheng, Y. Chen, W. Tang, and T. Lu Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors Arch. Pharm. Res. 35 2012 1723 1732
177. M. Cai, J. Hu, J.L. Tian, H. Yan, C.G. Zheng, and W.L. Hu Novel hybrids from N-hydroxyarylamide and indole ring through click chemistry as histone deacetylase inhibitors with potent antitumor activities Chin. Chem. Lett. 26 2015 675 680
178. X. Li, J. Hou, X. Li, Y. Jiang, X. Liu, W. Mu, Y. Jin, Y. Zhang, and W. Xu Development of 3-hydroxycinnamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity Eur. J. Med. Chem. 89 2015 628 637
179. T. Feng, H. Wang, H. Su, H. Lu, L. Yu, X. Zhang, H. Sun, and Q. You Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2) Bioorg. Med. Chem. 21 2013 5339 5354
180. H. Fu, L. Han, X. Hou, Y. Dun, L. Wang, X. Gong, and H. Fang Design, synthesis and biological evaluation of saccharin based N-hydroxybenzamides as histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. 23 2015 5774 5781
181. W. Lu, F. Wang, T. Zhang, J. Dong, H. Gao, P. Su, Y. Shi, and J. Zhang Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives Bioorg. Med. Chem. 22 2014 2707 2713
182. B. Gopalan, T. Ponpandian, V. Kachhadia, K. Bharathimohan, R. Vignesh, V. Sivasudar, S. Narayanan, B. Mandar, R. Praveen, N. Saranya, S. Rajagopal, and S. Rajagopal Discovery of adamantane based highly potent HDAC inhibitors Bioorg. Med. Chem. Lett. 23 2013 2532 2537
183. X. Zhang, J. Zhang, L. Tong, Y. Luo, M. Su, Y. Zang, J. Li, W. Lu, and Y. Chen The discovery of colchicine-SAHA hybrids as a new class of antitumor agents Bioorg. Med. Chem. 21 2013 3240 3244
184. D.T.K. Oanh, H.V. Hai, V.T.M. Hue, S.H. Park, H.J. Kim, B.W. Han, H.S. Kim, J.T. Hong, S.B. Han, and N.H. Nam Benzothiazole containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents Bioorg. Med. Chem. Lett. 21 2011 7509 7512
185. T.T. Tung, D.T.K. Oanh, P.T.P. Dung, V.T.M. Hue, S.H. Park, B.W. Han, Y. Kim, J.T. Hong, S.B. Han, and N.H. Nam New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents Med. Chem. 9 2013 1051 1057
186. N.H. Nam, T.L. Huong, D.T.M. Dung, P.T.P. Dung, D.T.K. Oanh, D. Quyen, L.T. Thao, S.H. Park, K.R. Kim, B.W. Han, J. Yun, J.S. Kang, Y. Kim, and S.B. Han Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents Eur. J. Med. Chem. 70 2013 477 486
187. X. Zhao, Q. Tan, Z. Zhang, and Y. Zhao 1,3,5-Triazine inhibitors of histone deacetylases: synthesis and biological activity Med. Chem. Res. 23 2014 5188 5196
188. K. Jin, S. Li, X. Li, J. Zhang, W. Xu, and X. Li Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as HDAC inhibitors Bioorg. Med. Chem. 23 2015 4728 4736
189. Q. Tan, Z. Zhang, J. Hui, Y. Zhao, and L. Zhu Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors Bioorg. Med. Chem. 22 2014 358 365
190. W. Yang, L. Li, X. Ji, X. Wu, M. Su, L. Sheng, Y. Zang, J. Li, and H. Liu Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors Bioorg. Med. Chem. 22 2014 6146 6155
191. W. Duan, J. Hou, X. Chu, X. Li, J. Zhang, J. Li, W. Xu, and Y. Zhang Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity Bioorg. Med. Chem. 23 2015 4481 4488
192. L. Wang, X. Hou, H. Fu, X. Pan, W. Xu, W. Tang, and H. Fang Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. 23 2015 4364 4374
193. W. Yang, L. Li, Y. Wang, X. Wu, T. Li, N. Yang, M. Su, L. Sheng, M. Zheng, Y. Zang, J. Li, and H. Liu Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors Bioorg. Med. Chem. 23 2015 5881 5890
194. S.H. Woo, S. Frechette, E.A. Khalil, G. Bouchain, A. Vaisburg, N. Bernstein, O. Moradei, S. Leit, M. Allan, M. Fournel, M.C. Trachy-Bourget, Z. Li, J.M. Besterman, and D. Delorme Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors J. Med. Chem. 45 2002 2877 2885
195. N. Nishino, B. Jose, R. Shinta, T. Kato, Y. Komatsu, and M. Yoshida Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors Bioorg. Med. Chem. 12 2004 5777 5784
196. J. Shen, R. Woodward, J.P. Kedenburg, X. Liu, M. Chen, L. Fang, D. Sun, and P.G. Wang Histone deacetylase inhibitors through click chemistry J. Med. Chem. 51 2008 7417 7427
197. L. Marek, A. Hamacher, F.K. Hansen, K. Kuna, H. Gohlke, M.U. Kassack, and T. Kurz Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells J. Med. Chem. 56 2013 427 436
198. T. Tashima, H. Murata, and H. Kodama Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors Bioorg. Med. Chem. 22 2014 3720 3731
199. S. Sharma, M. Ahmad, J.A. Bhat, A. Kumar, M. Kumar, M.A. Zargar, A. Hamid, and B.A. Shah Design, synthesis and biological evaluation of b-boswellic acid based HDAC inhibitors as inducers of cancer cell death Bioorg. Med. Chem. Lett. 24 2014 4729 4734
200. F.W. Peng, T.T. Wu, Z.W. Ren, J.Y. Xue, and L. Shi Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase Bioorg. Med. Chem. Lett. 25 2015 5137 5141
201. Y.M. Liu, H.Y. Lee, C.H. Chen, C.H. Lee, L.T. Wang, S.L. Pan, M.J. Lai, T.K. Yeh, and J.P. Liou 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells Eur. J. Med. Chem. 89 2015 320 330
202. V. Kachhadiaa, S. Rajagopal, T. Ponpandiana, R. Vignesha, K. Anandhana, D. Prabhub, P. Rajendran, S. Nidhyanandan, A.M. Roy, F.A. Ahamed, S. Narayanan, S. Rajagopal, S. Narayanan, and B. Gopalan Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts Eur. J. Med. Chem. 108 2016 274 286
203. V. Zwick, A. Nurisso, C. Simoes-Pires, S. Bouchet, N. Martinet, A. Lehotzky, J. Ovadi, M. Cuendet, C. Blanquart, and P. Bertrand Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates Bioorg. Med. Chem. Lett. 26 2016 154 159